Blend Composition + Dosage Chart
Blend Composition
What the source does confirm is the daily injection breakdown once the vial is reconstituted:
| Component | Per daily injection |
|---|---|
| GHK-Cu | ~1.7 mg |
| TB-500 | ~0.33 mg |
| BPC-157 | ~0.33 mg |
| Total | 2,330 mcg (2.33 mg) |
The source presents these as approximate figures; the component values as given (1.7 + 0.33 + 0.33 mg) sum to 2.36 mg rather than exactly 2.33 mg, a small rounding difference in the source itself, reproduced here as written. [7]
Dosage Chart
Once-daily subcutaneous injection, same time each day, no titration: the full dose is maintained throughout the 4-week cycle. [7]
| Phase | Daily dose | Units (U-100) | Volume |
|---|---|---|---|
| Weeks 1–4 (full cycle) | 2,330 mcg | 10 u | 0.10 mL |
Cycle: 4 weeks on, followed by 2–4 weeks off, to allow receptor resensitization and metabolic recovery. [7]
Reconstitution
70 mg vial, mixed to a working concentration before drawing a dose.
Add 3.0 mL of bacteriostatic water to the 70 mg vial to yield a final concentration of approximately 23.3 mg/mL. Ten units on a U-100 insulin syringe (0.10 mL) delivers the full daily dose of 2,330 mcg. [7]
Before reconstitution, store the lyophilized vial at −20 °C or below in dry conditions. Once reconstituted, store at 2–8 °C, protected from light, and avoid repeated freeze-thaw cycles; use within approximately 4 weeks (28 days) for optimal potency and safety. [7]
How It Works
The literature below is component literature: studies of the individual peptides in GLOW, not of the blend itself. No published study has tested this specific three-component combination in humans.
GHK-Cu stimulates collagen, elastin, and glycosaminoglycan synthesis, modulates metalloproteinases and their inhibitors, and promotes blood vessel and nerve outgrowth; it plays a physiological role in wound healing through fibroblast collagen production during tissue remodeling. [1][2][3]
BPC-157 is a pentadecapeptide isolated from human gastric juice, described in the literature as an anti-inflammatory agent supporting tissue repair in gastrointestinal, musculoskeletal, and wound contexts. See the full BPC-157 protocol page on this site for its detailed mechanism, pharmacokinetics, and citations.
TB-500 is a synthetic peptide derived from the active region of thymosin beta-4 (the peptide segment LKKTETQ), supporting actin-related cell migration, wound healing, and tendon repair. [5] In a rat model, a study evaluating BPC-157 and TB-500 together on Achilles tendon healing reported improved histopathological and biomechanical outcomes. [4]
No human safety or efficacy data exists for GLOW as a blended product. Individual component data come from in vitro, animal, and limited human pilot studies for each peptide separately; the safety, efficacy, and any pharmacokinetic interaction of the specific 1.7 mg GHK-Cu / 0.33 mg TB-500 / 0.33 mg BPC-157 combination used in this blend have not been studied in humans. GLOW, as a named product, does not have FDA approval, is not registered in Drugs@FDA, and has no established prescribing label; its individual components similarly lack FDA approval for any indication. [6] This section describes what the component literature reports; it is not a claim of safety or effectiveness for this blend in human use.
References
Component literature. None of these studies tested the GLOW blend itself.
[1] Regenerative and Protective Actions of the GHK-Cu Peptide · Pickart & Margolina, 2018, PMID 29986520
[2] GHK as a Cellular Pathway Modulator · 2015, PMID 26236730
[3] The Human Tri-Peptide GHK and Tissue Remodeling · 2008, PMID 18644225
[4] Effects of BPC-157 and TB-500 on Achilles Tendon Healing in Rats · 2026, PMID 42542926
[5] Doping Control Analysis of TB-500 · 2012, PMID 23084823
[6] GLOW overview · PeptideDosages
[7] GLOW 70 mg vial dosage protocol · PeptideDosages